{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:38:43Z","timestamp":1784115523614,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.semarthrit.2023.152208","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T20:56:26Z","timestamp":1682542586000},"page":"152208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Domain reporting in systemic sclerosis-related Raynaud's phenomenon: An OMERACT scoping review"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-4312","authenticated-orcid":false,"given":"Nancy","family":"Maltez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane L.","family":"Herrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Pauling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152208_bib0001","unstructured":"Walker, U.A., et\u00a0al., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. (0003-4967 (Print))."},{"key":"10.1016\/j.semarthrit.2023.152208_bib0002","unstructured":"Hughes, M., et\u00a0al., Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. (1462-0332 (Electronic))."},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0003","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","article-title":"Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a canadian national survey","volume":"50","author":"Bassel","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/key026","article-title":"The patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"58","author":"Pauling","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152208_bib0005","unstructured":"Herrick, A.L., Pathogenesis of Raynaud's phenomenon. (1462-0324 (Print))."},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0006","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/2397198318774307","article-title":"Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: a SCTC Vascular Working Group Report","volume":"3","author":"Pauling","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152208_bib0007","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/1744666X.2018.1464390","article-title":"The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis","volume":"14","author":"Pauling","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2023.152208_bib0008","unstructured":"Gladue, H., et\u00a0al., Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. (2151-4658 (Electronic))."},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0009","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0010","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","article-title":"Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"41","author":"Wigley","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152208_bib0011","unstructured":"Boers, M.A.-O.X., et\u00a0al., OMERACT Filter 2.1: Elaboration of the conceptual framework for outcome measurement in health intervention studies. (0315-162X (Print))."},{"key":"10.1016\/j.semarthrit.2023.152208_bib0012","unstructured":"Beaton, D.E.M.L., Grosskleg S, Shea B, Tugwell B eds., The OMERACT Handbook Version 2.1. https:\/\/omeract.org\/handbook\/. 2021."},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0013","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.semarthrit.2021.04.005","article-title":"Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020","volume":"51","author":"Maltez","year":"2021","journal-title":"Seminars in Arthritis Rheumat"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152208_bib0014","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3899\/jrheum.181097","article-title":"Core domain set selection according to OMERACT Filter 2.1: The OMERACT methodology","volume":"46","author":"Maxwell","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152208_bib0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3899\/jrheum.181096","article-title":"OMERACT Filter 2.1: Elaboration of the conceptual framework for outcome measurement in health intervention studies","volume":"46","author":"Boers","year":"2019","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152208_bib0016","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/art.40481","article-title":"Patient perceptions of the raynaud's condition score diary provide insight into its performance in clinical trials of raynaud's phenomenon: comment on the article by Denton et\u00a0al","volume":"70","author":"Pauling","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0017","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/acr.23475","article-title":"Multinational qualitative research study exploring the patient experience of raynaud's phenomenon in systemic sclerosis","volume":"70","author":"Pauling","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2023.152208_bib0018","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-022-06206-y","article-title":"The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis","author":"Hughes","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152208_bib0019","first-page":"S103","article-title":"Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis","volume":"30","author":"Pauling","year":"2012","journal-title":"Clin Exp Rheumatol Scleroderma Care Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152208_bib0020","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.semarthrit.2020.06.018","article-title":"Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review","volume":"50","author":"Pauling","year":"2020","journal-title":"Seminars in Arthritis Rheumat"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2023.152208_bib0021","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.5152\/eurjrheum.2020.19124","article-title":"New perspectives in the imaging of Raynaud's phenomenon","volume":"7","author":"Herrick","year":"2020","journal-title":"Eur j rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2133.1982.tb00905.x","article-title":"Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)","volume":"106","author":"Dowd","year":"1982","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152208_bib0023","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.44.11.754","article-title":"A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud syndrome","volume":"44","author":"Mohrland","year":"1985","journal-title":"Ann Rheumatic Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152208_bib0024","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00541510","article-title":"Clinical and laboratory effects of nifedipine in Raynaud's phenomenon","volume":"6","author":"Hawkins","year":"1986","journal-title":"Rheumatol int"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.47.1.43","article-title":"Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis","volume":"47","author":"McHugh","year":"1988","journal-title":"Ann rheumatic dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152208_bib0026","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/art.1780331103","article-title":"The post-occlusive hyperemic response in patients with systemic sclerosis","volume":"33","author":"Wigley","year":"1990","journal-title":"Arthritis rheumat"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152208_bib0027","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/ard.50.11.800","article-title":"A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases","volume":"50","author":"Torley","year":"1991","journal-title":"Ann rheumatic dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152208_bib0028","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/ard.51.11.1193","article-title":"Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis","volume":"51","author":"O'Reilly","year":"1992","journal-title":"Ann rheumatic dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0029","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic slcerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0049-0172(94)90098-1","article-title":"Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma","volume":"24","author":"Ter Borg","year":"1994","journal-title":"Seminars in Arthritis Rheumatism"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0031","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann int med"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.54.3.197","article-title":"Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study","volume":"54","author":"Belch","year":"1995","journal-title":"Ann rheumatic dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0033","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/37.9.952","article-title":"Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study","volume":"37","author":"Black","year":"1998","journal-title":"Br j rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0034","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","article-title":"Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"41","author":"Wigley","year":"1998","journal-title":"Arthritis rheumatism"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/mvre.1998.2124","article-title":"Laser doppler imaging\u2013a new technique for quantifying microcirculatory flow in patients with primary Raynaud's phenomenon and systemic sclerosis","volume":"57","author":"Clark","year":"1999","journal-title":"Microvasc res"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0036","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis rheumatism"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0037","first-page":"349","article-title":"A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis","volume":"18","author":"Herrick","year":"2000","journal-title":"Clin experimental rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0038","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0039","first-page":"786","article-title":"Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis","volume":"28","author":"Gardinali","year":"2001","journal-title":"The J rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152208_bib0040","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin experimental rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0041","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis rheumatism"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152208_bib0042","first-page":"1401","article-title":"Determination of fingertip lacticemy before and after cold stimulus in patients with primary Raynaud's phenomenon and systemic sclerosis","volume":"29","author":"Pucinelli","year":"2002","journal-title":"The J rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0043","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0026-2862(03)00018-9","article-title":"Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon","volume":"66","author":"Clark","year":"2003","journal-title":"Microvascular res"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152208_bib0044","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.0022-202X.2005.23938.x","article-title":"Infrared-mediated hyperthermia is effective in the treatment of scleroderma-associated Raynaud's phenomenon [2]","volume":"125","author":"Foerster","year":"2005","journal-title":"J Investigative Dermatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0045","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/039463200501800420","article-title":"Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon","volume":"18","author":"Salsano","year":"2005","journal-title":"Int j immunopathol pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0046","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/rheumatology\/kel330","article-title":"The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon","volume":"46","author":"Anderson","year":"2007","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0047","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2230.2005.01995.x","article-title":"Infrared-monitored cold response in the assessment of Raynaud's phenomenon","volume":"31","author":"Foerster","year":"2006","journal-title":"Clin experimental dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152208_bib0048","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kel038","article-title":"Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol","volume":"45","author":"Milio","year":"2006","journal-title":"Rheumatology (Oxford, England)"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152208_bib0049","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jdermsci.2006.11.006","article-title":"A cold-response index for the assessment of Raynaud's phenomenon","volume":"45","author":"Foerster","year":"2007","journal-title":"J dermatol sci"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152208_bib0050","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis rheumatism"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0051","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"The J rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0052","first-page":"1830","article-title":"Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study","volume":"35","author":"Kawald","year":"2008","journal-title":"The J rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0053","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis and rheumatism"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0054","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-009-1251-7","article-title":"The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients","volume":"28","author":"Rosato","year":"2009","journal-title":"Clin rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152208_bib0055","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3899\/jrheum.090187","article-title":"Laser Doppler perfusion imaging is useful in the study of Raynaud's phenomenon and improves the capillaroscopic diagnosis","volume":"36","author":"Rosato","year":"2009","journal-title":"The J rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152208_bib0056","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis","volume":"36","author":"Schiopu","year":"2009","journal-title":"The J rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0057","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar3112","article-title":"Comparison of laser Doppler imaging, fingertip lacticemy test, and nailfold capillaroscopy for assessment of digital microcirculation in systemic sclerosis","volume":"12","author":"Correa","year":"2010","journal-title":"Arthritis res therapy"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152208_bib0058","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3899\/jrheum.091356","article-title":"Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study","volume":"37","author":"Cutolo","year":"2010","journal-title":"The J rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152208_bib0059","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/MAJ.0b013e3181eecfad","article-title":"The different photoplethysmographic patterns can help to distinguish patients with primary and sclerodermic Raynaud phenomenon","volume":"340","author":"Rosato","year":"2010","journal-title":"Am J Med Sci"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0060","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0061","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthr rheumat"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152208_bib0062","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.mvr.2011.03.007","article-title":"Influence of the cold challenge on the discriminatory capacity of the digital distal-dorsal difference in the thermographic assessment of Raynaud's phenomenon","volume":"82","author":"Pauling","year":"2011","journal-title":"Microvascular res"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152208_bib0063","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/03009742.2010.530293","article-title":"The combination of laser Doppler perfusion imaging and photoplethysmography is useful in the characterization of scleroderma and primary Raynaud's phenomenon","volume":"40","author":"Rosato","year":"2011","journal-title":"Scand j rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152208_bib0064","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/rheumatology\/ker188","article-title":"Laser Doppler perfusion imaging in systemic sclerosis impaired response to cold stimulation involves digits and hand dorsum","volume":"50","author":"Rosato","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0065","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","article-title":"A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon","volume":"72","author":"Hummers","year":"2013","journal-title":"Ann rheumatic dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152208_bib0066","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.141437","article-title":"Use of laser speckle contrast imaging to assess digital microvascular function in primary raynaud phenomenon and systemic sclerosis: a comparison using the raynaud condition score diary","volume":"42","author":"Pauling","year":"2015","journal-title":"The J rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152208_bib0067","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10067-015-3119-3","article-title":"Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis","volume":"35","author":"Bellando-Randone","year":"2016","journal-title":"Clin rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0068","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00296-016-3584-2","article-title":"Diagnosis of Raynaud's phenomenon by 99mTc-pertechnetate hand perfusion scintigraphy: a pilot study","volume":"36","author":"Pavlov-Dolijanovic","year":"2016","journal-title":"Rheumatol int"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152208_bib0069","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis rheumatol (Hoboken, N.J.)."},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0070","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and safety of selexipag in adults with raynaud's phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis rheumatol (Hoboken, N.J.)"},{"issue":"mxw, 0165035","key":"10.1016\/j.semarthrit.2023.152208_bib0071","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2017.05.003","article-title":"Quantitative outcome measures for systemic sclerosis-related Microangiopathy - Reliability of image acquisition in Nailfold Capillaroscopy","volume":"113","author":"Dinsdale","year":"2017","journal-title":"Microvasc res"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152208_bib0072","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin b injection for raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta dermato-venereologica"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152208_bib0073","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.40457","article-title":"A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-Related Raynaud's phenomenon","volume":"70","author":"Wilkinson","year":"2018","journal-title":"Arthr rheumatol (Hoboken, N.J.)"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152208_bib0074","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s10067-019-04762-4","article-title":"Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series","volume":"38","author":"Dhaliwal","year":"2019","journal-title":"Clinical rheumatol"},{"issue":"4 Supplement 119","key":"10.1016\/j.semarthrit.2023.152208_bib0075","first-page":"97","article-title":"Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis","volume":"37","author":"Frech","year":"2019","journal-title":"Clin experimental rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152208_bib0076","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/acr.23729","article-title":"Evolving symptom characteristics of raynaud's phenomenon in systemic sclerosis and their association with physician and patient-reported assessments of disease severity","volume":"71","author":"Pauling","year":"2019","journal-title":"Arthritis care res"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152208_bib0077","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.180818","article-title":"Factors influencing raynaud condition score diary outcomes in systemic sclerosis","volume":"46","author":"Pauling","year":"2019","journal-title":"The J Rheumatol"},{"issue":"101548923","key":"10.1016\/j.semarthrit.2023.152208_bib0078","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fphar.2019.00293","article-title":"Aminaphtone efficacy in primary and secondary raynaud's phenomenon: a feasibility study","volume":"10","author":"Ruaro","year":"2019","journal-title":"Front pharmacol"},{"issue":"101548923","key":"10.1016\/j.semarthrit.2023.152208_bib0079","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fphar.2019.00360","article-title":"Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon","volume":"10","author":"Ruaro","year":"2019","journal-title":"Front pharmacol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:12:39Z","timestamp":1758733959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":79,"alternative-id":["S0049017223000501"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152208","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Domain reporting in systemic sclerosis-related Raynaud's phenomenon: An OMERACT scoping review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152208"}}